Langer, Robert S.,Weight, Alisha K.,Larson, Alyssa M.,Klibanov, Alexander M.,Love, Kevin,Crane, Alan
申请号：
AU2020202240
公开号：
AU2020202240A1
申请日:
2020.03.30
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
#$%^&*AU2020202240A120200423.pdf#####The present invention is directed to liquid pharmaceutical formulations for injection administration, wherein the formulation comprises one or more proteins, one or more viscosity-reducing organophosphates and a pharmaceuticaly acceptable solvent. The formulation has a viscosity from about 1 cP to about 50 cP at 25C measured using a cone and plate viscometer. The absolute viscosity of this formulation is less than the absolute viscosity of the otherwise same formulation comprising an equivalent amount of sodium phosphate in place of the organophosphate, and wherein the absolute viscosity in each case is an extrapolated zero-shear viscosity. Proteins are high molecular weight proteins having a molecular weight of between about 70 kDa upto 500kDa, are enzymes, antibodies, fusion proteins or PEGylated proteins. The formulations also behaves rheologically as a Newtonian liquid at conditions under which it would be administrated to a subject in need.WO 2015/038782 PCT/US2014/055210 350 -m-0.25 M Phosphate Buffer 300 --. 1M TPP -- 0.1 M TPP-APMI 250 200 150 100 150 0 50 100 150 200 250 300 [Biosimilar Avastin], mg/mL FIG. 1 .1/
